DECADRON Eye Drops Cleared for Continued Generic Production
Published Date: 4/9/2025
Notice
Summary
The FDA says DECADRON eye drops (0.1% phosphate) weren’t pulled from shelves because of safety or effectiveness problems. This means generic drug makers can keep getting approval to sell their versions, so patients and pharmacies won’t face shortages or price hikes. Everyone who uses or sells this medicine can breathe easy—no sudden changes or costs coming!
Analyzed Economic Effects
1 provisions identified: 1 benefits, 0 costs, 0 mixed.
DECADRON Generics Remain Approvable
If you use DECADRON eye drops (dexamethasone sodium phosphate) equivalent to 0.1 percent phosphate, the FDA has determined the product was not withdrawn for reasons of safety or effectiveness. That means the FDA will not begin procedures to withdraw approvals of abbreviated new drug applications (ANDAs) that refer to this product, and the agency will continue to approve ANDAs that refer to it so long as they meet legal and regulatory requirements.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-04978, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA is delaying a new rule about nonprescription drugs that have extra conditions for use. Originally set to start on March 21, 2025, the rule’s start date is now pushed back to May 27, 2025, to allow more time for review. This affects drug makers and consumers by giving everyone extra time to prepare for the new requirements without any immediate cost changes.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
2026-20441, Medical Devices; Cardiovascular Devices; Classification of the Hyperoxia Monitoring Device Adjunct to Pulse Oximetry
The FDA is officially putting the hyperoxia monitoring device that works with pulse oximeters into a safer, easier-to-manage category called Class II. This change, effective October 6, 2026, means the device will have special safety rules but fewer regulatory hurdles, helping patients get access to this cool tech faster. Medical device makers and healthcare providers will feel the impact, with smoother approval processes and no big new costs expected.
Previous / Next Documents
Previous: 2025-06045, GE HealthCare, et al.; Withdrawal of Approval of 18 New Drug Applications
The FDA is officially pulling the plug on 18 drug approvals because the companies told them these medicines aren’t being sold anymore. This means those drugs won’t be available, but no one’s losing money or access since they’re already off the shelves. If you’re involved with these drugs, now’s the time to update your records and plans!
Next: 2025-06047, Type VII Veterinary Master File for Research and Development and Risk Reviews; Draft Guidance for Industry; Reopening of the Comment Period
The FDA is giving folks more time to share their thoughts on a new draft guide about Type VII Veterinary Master Files, which help with animal medicine research and safety checks. This extension means companies and researchers can better prepare their comments before the FDA finalizes the rules. No extra costs or deadlines changed yet, but staying tuned is smart!